BIOA · BioAge Labs
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $7.45
Note written ·
Price against the kill line
25.5% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $7.45, on record since 11 November 2026. The shares are down 46.6% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $7.45, which would put the shares above their 50-day average and show them leading the index. A QUELL-CV topline showing clear hsCRP separation from placebo across dose arms would also show the shares leading.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 0.3
- Revenue, change on a year (%)
- −85.5
- Operating margin (%)
- −12554.0
- Free cash flow, four quarters ($M)
- −103
- Net cash, cash less debt ($M)
- 278
- Enterprise value to sales (×)
- −2.7
- Free-cash-flow yield (%)
- −40.4
All filed numbers
What BioAge Labs reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 0.3 | −85.5 | −12554.0 |
| first filed | 2.5 | +1.6 | −1196.8 |
| first filed | 2.8 | +91.0 | −915.4 |
| first filed | 3.1 | — | −923.4 |
| first filed | 2.1 | — | −1126.6 |
| first filed | 2.4 | — | −1027.0 |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −108 | −33.5 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +28.1 |
| Operating cash flow ($M) | −103 |
| Capital spending ($M) | 0.5 |
| Free cash flow ($M) | −103 |
| Cash and short-term investments ($M) | 284 |
| Debt ($M) at 31 December 2025, filed 24 March 2026; non-current long-term debt plus current maturities | 2.6 |
| Net cash, cash less debt ($M) at 31 December 2025, filed 5 November 2026 | 278 |
| Deferred revenue ($M) −38.3% on a year | 4.6 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 0.6 |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 346 |
| Market value ($M) | 255 |
| Enterprise value, market value plus net debt ($M) | −23.4 |
| Enterprise value to sales (×) | −2.7 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 0.7 |
| Free-cash-flow yield (%) | −40.4 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 7.5% of shares outstanding sold short, 3.7 days of average trading to cover, +4.8% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $7.8M |
The thesis
BioAge Labs' shares are more likely to lag the S&P 500 over the next three months than to beat it. The case rests on one pending event, the QUELL-CV Phase 2 topline for its oral NLRP3 inhibitor BGE-102, which the company's 5 November 2026 third-quarter release placed in the fourth quarter of 2026. The hsCRP result against placebo settles it.
The shares closed at $5.87 on 11 November 2026, 77.4% below the 52-week intraday high of $25.95 set on 6 July 2026. They sit below the 50-day average of $6.76 and the 200-day average of $15.25, and the three-month change is −43.7%. Two brokers still rate the shares Overweight or Buy with $40 targets, per company news on 9 November 2026, so the price already reflects heavy doubt about the readout.
BioAge says enrollment of about 160 participants is complete. Counted from the 8 September 2026 enrollment announcement, the last participant finishes 12 weeks of dosing around 1 December 2026. That is an estimate, and a topline released before that date would show it wrong.
Bullish and bearish views on BioAge Labs, Inc.
The bull case on BioAge Labs, Inc. (BIOA), in brief: the topline window is one quarter. The bear case: the third quarter missed estimates.
Bull case
- The topline window is one quarter. The 5 November 2026 release anticipates QUELL-CV topline data in the fourth quarter of 2026, narrowing the earlier second-half guidance.
- Phase 1 showed strong biomarker activity. BioAge's 5 August 2026 update reported median high-sensitivity C-reactive protein (hsCRP, a blood marker of inflammation) reductions of 86% from baseline at 60 mg and 120 mg once daily, with no serious adverse events.
- Cash covers the readout. BioAge reported cash and marketable securities of about $352.3 million at 30 September 2026 and says they fund operations through 2029.
- Brokers kept high targets after the report. Piper Sandler maintained Overweight and lowered its target to $40, and BTIG reiterated Buy with a $40 target, both on 9 November 2026, according to company news.
- A second program is dosing. The first participant in QUELL-DME, a roughly 180-participant diabetic macular edema trial, was dosed in September 2026; topline is expected in the second half of 2027.
Bear case
- The third quarter missed estimates. Net loss was $33.5 million, or $0.73 per share, against a $0.59 loss expected in the Benzinga consensus on 5 November 2026. Collaboration revenue was $0.3 million, against $1.644 million expected.
- Spending is rising ahead of any product. Research and development expense was $30.2 million in the quarter ended 30 September 2026, up from $18.5 million a year earlier, mostly on BGE-102 trial and manufacturing costs.
- Cash fell during the quarter. Cash and marketable securities were $381.3 million at 30 June 2026 and $352.3 million at 30 September 2026, per the company's results.
- The endpoint is a biomarker. QUELL-CV's primary endpoint is 12-week percent change in hsCRP. A good result would not show fewer cardiovascular events.
- No readout date exists. BioAge gives only the fourth quarter, and its 11 November 2026 announcement concerned investor conference appearances, not a data date.
Price setup
The shares closed at $5.34 on 6 November 2026, $5.69 on 9 November 2026, $5.78 on 10 November 2026 and $5.87 on 11 November 2026. The 52-week closing low is $4.84, set on 16 October 2026. The close three months earlier, on 13 August 2026, was $10.43.
The last close is below both the 50-day average of $6.76 and the 200-day average of $15.25. A close above the 50-day average would be the first sign of the shares leading again before any data arrive. A close under $4.84 would set a new 52-week closing low without a clinical disclosure to explain it.
The gap between the $40 broker targets and the $5.87 close is wide. Neither the price nor the targets resolve until QUELL-CV reports.
Catalysts ahead
- ~1 December 2026 (est.): Earliest completion of 12 weeks of dosing for the last QUELL-CV participant, counted from the 8 September 2026 enrollment announcement. Sets the earliest plausible point for the topline; this is an analyst estimate, not company guidance.
- ~31 December 2026 (est.): End of BioAge's guided fourth-quarter 2026 window for the QUELL-CV topline; no release date has been announced. The hsCRP dose response versus placebo and the safety data decide whether the Phase 1 result carries into a larger obese, inflamed population.
- ~31 December 2026 (est.): BioAge's planned year-end 2026 IND filing for its first APJ agonist program. A secondary pipeline milestone; it matters less than the QUELL-CV topline.
What would change the view
A daily close above $7.45, which would put the shares above their 50-day average and show them leading the index. A QUELL-CV topline showing clear hsCRP separation from placebo across dose arms would also show the shares leading.
What it trades with
BIOA trades on its own clinical event, not on a sector or index driver. BioAge's Novartis collaboration was amended in September 2026, which cut third-quarter collaboration revenue through a $1.7 million cumulative catch-up adjustment. Other NLRP3 inhibitor developers share the same mechanism and may move on a BGE-102 result.
The evidence, claim by claim (7)
- BioAge anticipates QUELL-CV topline data in the fourth quarter of 2026; enrollment of about 160 participants is complete. The primary endpoint is 12-week percent change in hsCRP. BioAge Labs Q3 2026 results, 8-K exhibit 99.1 · as of
- Cash and marketable securities were about $352.3 million at 30 September 2026; BioAge says they fund operations through 2029. BioAge Labs Q3 2026 results, 8-K exhibit 99.1 · as of
- Third-quarter net loss was $33.5 million ($0.73 per share) versus $20.2 million ($0.56) a year earlier; R&D expense was $30.2 million versus $18.5 million. BioAge Labs Q3 2026 results, 8-K exhibit 99.1 · as of
- Third-quarter collaboration revenue was $0.3 million versus $2.1 million a year earlier, reflecting a $1.7 million cumulative catch-up adjustment tied to a September 2026 Novartis agreement amendment. BioAge Labs Q3 2026 results, 8-K exhibit 99.1 · as of
- Third-quarter EPS of $(0.73) missed the $(0.59) estimate; sales of $298,000 missed the $1.644 million estimate. Benzinga, 5 November 2026 · as of
- Phase 1 showed median hsCRP reductions of 86% from baseline at 60 mg and 120 mg once daily, with no serious adverse events. BioAge Labs second-quarter results, 5 August 2026 · as of
- Piper Sandler maintained Overweight and lowered its price target to $40; BTIG reiterated Buy with a $40 target. Company news headlines, 9 November 2026 · as of
Sources
Related · shared themes
IRON
Disc Medicine
Disc Medicine's shares are modestly favoured to beat the S&P 500 over three months because bitopertin passed its Phase 3 APOLLO trial on 19…
MANE
Veradermics
Veradermics' hair-loss pill VDPHL01 has finished its male trials with clean 12-month safety and cash of $798.4M guided into 2030. The case…
SMMT
Summit Therapeutics
Summit Therapeutics' case rests on FDA approval of ivonescimab in EGFR-mutant lung cancer by the 14 November 2026 goal date. The agency's…
ZLAB
Zai Lab
Zai Lab's shares are modestly more likely to beat the S&P 500 over three months on zoci, its DLL3 cancer drug with an 81.8% first-line…